RxSight (RXST) Insider Corley Jesse Anderson Buys 37,037 Shares
Executives at RxSight, Inc. increased their stakes on June 17, 2026, with significant purchases amid a challenging market.
Reviewed by automated data checks against the source filing. How we make and check alerts
Corley Jesse Anderson bought 37,037 shares of RxSight, Inc. ($RXST) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RXST is up 15.7% after 1 week, up 20.9% after 1 month and down 1.7% to date (from the $4.59 close on Jun 17, 2026).
RXST
RxSight, Inc.
Key Points
- On June 17, 2026, several insiders at RxSight, Inc. bought a total of 185,105 shares, with each acquiring 37,037 shares at a trading price of $4.73.
- The stock is currently trading near its 52-week low of $4.48, which may indicate a strategic buying opportunity for these insiders.
- Analysts maintain a consensus 'Hold' rating on RxSight, with a mean price target of $7.79, suggesting potential upside from current levels.
Get $RXST trade alerts by text
We text you when insiders, Congress or big funds trade $RXST. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated RxSight, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at RxSight, Inc.
On June 17, 2026, multiple insiders at RxSight, Inc. (NASDAQ: RXST) bought shares of the company, with each individual acquiring 37,037 shares. This group of insiders includes Corley Jesse Anderson, Julie Andrews, Tamara Fountain, Shweta Maniar, Link William Phd, and Robert Palmisano. With the stock trading at $4.73 at the time of the purchases, this action reflects a strong commitment from the company's executives.
What Changed in Insider Positions
The recent transactions increased the insiders' stakes in RxSight, reflecting confidence in the company’s future. Each insider purchased 37,037 shares, adding a total of 185,105 shares to their holdings on this date. This collective buying indicates a unified belief in the company’s growth prospects.
Analysts Set New Price Targets
Analysts have mixed views on RxSight, Inc. On September 22, 2026, Jefferies maintained a 'Hold' rating with a price target of $5.75, down from $6.50. B of A Securities also kept an 'Underperform' rating with a target of $5.50, down from $6.50. Meanwhile, Stifel maintained a 'Hold' rating with a price target of $7.00, decreased from $8.00. Overall, analysts have set a mean price target of $7.79, suggesting that the stock could have room to grow from its current levels.
Stock Performance Context
Currently, RxSight's shares are trading near their 52-week low of $4.48, with a high of $13.22. The stock's recent performance may reflect broader market conditions, and insider buying at this price point could indicate a belief in a turnaround. The stock closed at $5.20 prior to these transactions, showing a potential opportunity for recovery.
What RxSight, Inc. Does
RxSight, Inc. is a medical technology company based in Aliso Viejo, California. It specializes in developing light adjustable lenses for cataract surgery, allowing for customized visual correction. The recent insider purchases come at a time when the company is navigating a competitive landscape in the healthcare sector.
What's Next for RxSight
Investors should keep an eye on the upcoming earnings report scheduled for November 4, 2026. The recent insider transactions reflect positions as of June 17 and may not represent current holdings. As the company continues to innovate in the medical devices space, it will be important to watch for further developments and analyst updates.
Related Filing Alerts
Source: Corley Jesse Anderson's Form 4 filing on $RXST (Jun 17, 2026). Find the original filing: RXST Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts